https://www.lucence.com/zh-hk/news-updates/dr-eric-topol-calls-chip-cardiovascular-risk-driver 2026-03-20 https://www.lucence.com/zh-hk/news-updates/lucence%2C-dxd-hub-and-nccs-launch-s%246m-research-collaboration-to-advance-cancer-diagnostics-through-ai-and-patient-centric-research 2026-03-17 https://www.lucence.com/zh-hk/news-updates/lucence-and-partners-pathology-collaborate-to-advance-cancer-diagnostics-in-malaysia 2026-03-05 https://www.lucence.com/zh-hk/news-updates/lucence-ceo-dr.-tan-min-han-featured-in-the-straits-times%3A-the-future-of-precision-health-and-longevity 2026-01-28 https://www.lucence.com/zh-hk/news-updates/lucence-launches-cardiohemerisk%E2%84%A2-in-the-u.s.-to-identify-early-risk-markers-associated-with-heart-attack%2C-stroke%2C-and-leukemia 2026-01-12 https://www.lucence.com/zh-hk/news-updates/lucence-demonstrates-combined-ctdna-and-ctrna-liquid-biopsy-improves-diagnostic-yield-at-asco-2025 2025-11-19 https://www.lucence.com/zh-hk/news-updates/agilus-diagnostics-and-lucence-announce-strategic-collaboration-to-advance-cancer-testing-services-in-india 2025-11-10 https://www.lucence.com/zh-hk/news-updates/mayo-clinic-laboratories-and-lucence-announce-strategic-collaboration-to-enhance-cancer-testing-services 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-secures-moldx-approval-for-liquidhallmark%C2%AE-ctdna-and-ctrna-liquid-biopsy-test-to-advance-non-invasive-cancer-diagnostics 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-announces-expanded-access-for-liquidhallmark%C2%AE-liquid-biopsy-test-through-participation-across-regence-plans 2025-11-11 https://www.lucence.com/zh-hk/news-updates/lucence-and-diagnostics-development-hub-(dxd-hub)-collaborate-on-expanding-multi-cancer-early-detection-testing-to-alternative-sample-types 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-showcases-liquid-biopsy-tech-for-earlier-cancer-detection-at-2024-asco-annual-meeting 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-confirms-comprehensive-medicare-coverage-for-liquidhallmark%C2%AE-and-demonstrates-sensitive-detection-of-lung-cancer-biomarkers-in-prospective-study 2025-11-10 https://www.lucence.com/zh-hk/news-updates/interim-results-from-liquik-prospective-study-released-at-wclc-2023 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-announces-cpt-pla-code-granted-to-liquidhallmark%C2%AE 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-and-innovent-announce-strategic-collaboration-on-bile-duct-cancer 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-showcases-liquid-biopsy-tech-for-earlier-cancer-detection-at-2023-asco-annual-meeting 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-launches-lucenceinsight-to-detect-cancer-earlier 2025-11-11 https://www.lucence.com/zh-hk/news-updates/lucence-secures-us-medicare-approval-for-its-cancer-tests 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark%C2%AE-assay-in-lung-cancer 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-shares-promising-interim-data-from-liquik-prospective-study-at-islb-2022 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-and-omnigen-partner-to-bring-amplicon-based-liquid-biopsy-tests-to-turkey 2025-11-11 https://www.lucence.com/zh-hk/news-updates/lucence-collaborates-with-national-cancer-centre-singapore-to-launch-prospective-liquid-biopsy-study-for-prostate-cancer 2025-11-11 https://www.lucence.com/zh-hk/news-updates/local-study-demonstrates-synergies-of-using-blood-based-liquid-biopsies-to-complement-tissue-biopsies-for-lung-cancer-diagnosis 2025-11-11 https://www.lucence.com/zh-hk/news-updates/lucence-presents-data-at-2022-world-conference-on-lung-cancer-(wclc)-supporting-utility-of-amplicon-based-liquid-biopsy 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-showcases-promising-data-on-ctdna-and-ctrna-liquid-biopsy-assay-for-lung-cancer-at-2022-asco-annual-meeting 2025-11-10 https://www.lucence.com/zh-hk/news-updates/lucence-announces-publication-of-validation-study-for-liquidhallmark-ctdna-liquid-biopsy-assay 2026-01-12 https://www.lucence.com/zh-hk/news-updates/lucence%E2%80%99s-liquidhallmark-liquid-biopsy-assay-expands-to-include-cfrna 2025-11-11 https://www.lucence.com/zh-hk/news-updates/lucence-launches-first-liquid-biopsy-screening-study-in-partnership-with-the-va-palo-alto-healthcare-system 2026-01-12 https://www.lucence.com/zh-hk/news-updates/astrazeneca-and-lucence-collaborate-in-south-east-asia-to-bring-hrd-testing-to-ovarian-cancer-patients-to-guide-parpi-treatment 2025-11-11 https://www.lucence.com/zh-hk/news-updates/lucence-and-yemaachi-launch-the-amber-study-to-detect-and-characterize-genomic-alterations-in-breast-cancer-in-women-in-africa-and-expand-liquid-biopsy-access 2026-01-12 https://www.lucence.com/zh-hk/news-updates/lucence-presents-data-at-esmo-2021-showing-liquid-biopsy-detects-actionable-genomic-alterations-in-bladder-cancer-patients-undergoing-immunotherapy 2026-01-12 https://www.lucence.com/zh-hk/news-updates/lucence-announces-commercial-availability-of-tissue500-for-comprehensive-targeted-therapy-matching%2F 2025-11-11 https://www.lucence.com/zh-hk/news-updates/asco21-evidence-medical-advisory-board%2F 2026-01-12 https://www.lucence.com/zh-hk/news-updates/liquik-study-for-lung-cancer%2F 2025-11-10 https://www.lucence.com/zh-hk/news-updates/waseda-university-cancer-screening-platform%2F 2025-11-11 https://www.lucence.com/zh-hk/news-updates/us-clia-certification%2F 2025-11-10 https://www.lucence.com/zh-hk/news-updates/asco20-evidence-amplimark-for-lung-cancer%2F 2025-11-11 https://www.lucence.com/zh-hk/news-updates/amplimark-for-blood-cancers%2F 2025-11-11 https://www.lucence.com/zh-hk/news-updates/series-a-ihh-healthcare%2F 2025-11-11